Coya Therapeutics, Inc. (COYA) Stock

Coya Therapeutics, Inc. (COYA) is a Healthcare stock trading at $4.86 (as of 2026-08-21), with a market capitalization of $114.01M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing medicinal product candidates designed to modulate regulatory T-cell (Treg) function. Its pipeline includes COYA 101 for amyotrophic lateral sclerosis, additional Treg-focused biologics and exosome-based therapies for neurodegenerative and autoimmune indications, and related candidates in IND-enabling, preclinical, or discovery stages.

Understand Coya Therapeutics, Inc.: how it makes money

Coya Therapeutics develops proprietary medicines that modulate regulatory T cells (Tregs), including an autologous regulatory T-cell candidate (COYA 101) for amyotrophic lateral sclerosis (ALS), and earlier pipeline programs such as Treg-enhancing biologics and Treg-derived exosomes, with revenue and commercialization not described in the provided facts.

The company is structured to create value by progressing its Treg-modulating pipeline programs, such as COYA 101 (ALS), through clinical development and regulatory steps, because meaningful revenue would depend on successful advancement toward commercialization.

Business quality (Weak): The provided facts show a clinical-stage pipeline (including COYA 101 Phase 2a completion for ALS) but no disclosed segment revenue, and the latest quarter shows 0.0B revenue with a deeply negative operating margin, so near-term fundamentals are dominated by development execution and trial progress.

Bull case

  • COYA 101 has completed Phase 2a for ALS: The lead autologous regulatory T-cell candidate (COYA 101) is reported to have completed Phase 2a clinical testing for amyotrophic lateral sclerosis.
  • Broad Treg-based modality platform: The pipeline is built around multiple Treg-modulating approaches, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Bear case

  • No revenue in the latest reported quarter: For the period ending 2026-03-31, revenue is reported as 0.0B in the provided facts.
  • Material operating losses: The provided operating margin for 2026-03-31 is -3042.1, indicating significant operating loss.
  • Trial scale captured by the provided operating metric is limited: The only provided operational metric, Number of Patients Randomly Assigned, is 38, which is a limited datapoint for validating efficacy and safety.
Valuation — source: SEC EDGAR (first-party)
Price$4.86
Market Cap$114.01M
Price / Book2.63
Price / Sales26.45
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$7.95M
Net Margin-267.1%
Revenue Growth (YoY)123.6%
EPS Growth (YoY)29.6%
Financial Health — source: SEC EDGAR
Altman Z-Score7.87 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderGREENLIGHT CAPITAL INC ($9.44M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOArun Swaminathan
Employees8
CountryUS
IPO Date2022-12-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • TuHURA Biosciences, Inc. (HURA)
  • Anixa Biosciences, Inc. (ANIX)
  • Genelux Corporation (GNLX)
  • Inovio Pharmaceuticals, Inc. (INO)
  • Neonc Technologies Holdings, Inc. (NTHI)
  • Cumberland Pharmaceuticals Inc. (CPIX)
  • Rafael Holdings, Inc. (RFL)
  • Polaryx Therapeutics, Inc. Common Stock (PLYX)
COYA earnings history · COYA institutional & insider holders · COYA KPIs & operating metrics · COYA financials · COYA investor presentations & press releases · COYA SEC filings · COYA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.